Treatment use in prognostic model research: a systematic review of cardiovascular prognostic studies
نویسندگان
چکیده
Background: Ignoring treatments in prognostic model development or validation can affect the accuracy and transportability of models. We aim to quantify the extent to which the effects of treatment have been addressed in existing prognostic model research and provide recommendations for the handling and reporting of treatment use in future studies. Methods: We first describe how and when the use of treatments by individuals in a prognostic study can influence the development or validation of a prognostic model. We subsequently conducted a systematic review of the handling and reporting of treatment use in prognostic model studies in cardiovascular medicine. Data on treatment use (e.g. medications, surgeries, lifestyle interventions), the timing of their use, and the handling of such treatment use in the analyses were extracted and summarised. Results: Three hundred two articles were included in the review. Treatment use was not mentioned in 91 (30%) articles. One hundred forty-six (48%) reported specific information about treatment use in their studies; 78 (26%) provided information about multiple treatments. Three articles (1%) reported changes in medication use (“treatment drop-in”) during follow-up. Seventy-nine articles (26%) excluded treated individuals from their analysis, 80 articles (26%) modelled treatment as an outcome, and of the 155 articles that developed a model, 86 (55%) modelled treatment use, almost exclusively at baseline, as a predictor. Conclusions: The use of treatments has been partly considered by the majority of CVD prognostic model studies. Detailed accounts including, for example, information on treatment drop-in were rare. Where relevant, the use of treatments should be considered in the analysis of prognostic model studies, particularly when a prognostic model is designed to guide the use of certain treatments and these treatments have been used by the study participants. Future prognostic model studies should clearly report the use of treatments by study participants and consider the potential impact of treatment use on the study findings.
منابع مشابه
Prognostic Value of BAALC Expression in Pediatric Acute Myeloid Leukemia: A Systematic Review
Background: Acute myeloid leukemia (AML) is a malignant disorder involving blood cells, characterized by obstructed or distorted differentiation of hematopoietic stem cells. In cytogenetically normal AML (CN AML), molecular abnormalities in NPM, FLT3, CEBPA, and BAALC genes are observed. Initially, high BAALC (Brain and Acute Leukemia Cytoplasmic gene) expression was introduced in a study on AM...
متن کاملAuthor's response to reviews Title: Treatment Use in Prognostic Model Research: a Systematic Review of Cardiovascular Prognostic Studies Authors:
Title: Treatment Use in Prognostic Model Research: a Systematic Review of Cardiovascular Prognostic Studies Authors: Romin Pajouheshnia ([email protected]) Johanna Damen ([email protected]) Rolf Groenwold ([email protected]) Karel Moons ([email protected]) Linda Peelen ([email protected]) Version: 1 Date: 01 Sep 2017 Author’s response to reviews: De...
متن کاملComplete Blood Count Parameters as Prognostic Factor of Stroke: A Systematic Review
Introduction: Stroke is known as a common cause of disability all over the world. Stroke prognosis estimation has always been a topic of interest. In this study, it was tried to investigate the prognostic value of laboratory findings of complete blood count in a systematic review. Methods: In this systematic review, literature from Medline via (PubMed, Ovid) Embase, Scopus, Cochrane Library, a...
متن کاملP 20: Neutrophil to Lymphocyte Ratio as a Prognostic Marker in Glioblastoma Multiforme: a Systematic Review and Meta-Analysis
لطفاً به چکیده انگلیسی مراجعه شود.
متن کاملPrognostic Value of EVI1 Expression in Pediatric Acute Myeloid Leukemia: A Systematic Review
Acute myeloid leukemia (AML) as a distortion of blood cells involves the differentiation of hematopoietic stem cells. Several studies established the irregular overexpression of specific genes is a common finding in patients with AML. The ectopic viral integration site-1 (EVI1) gene is a proto-oncogene subject to alternative splicing, and encodes a zinc-finger protein that acts as a tr...
متن کامل